Literature DB >> 6230953

Comparison of four opioid analgesics as supplements to nitrous oxide anesthesia.

M M Ghoneim, J Dhanaraj, W W Choi.   

Abstract

The hemodynamic changes, plasma norepinephrine levels, pupil size, and rapidity of postoperative mental recovery were measured and compared in 72 patients randomly assigned in a double-blind manner to receive either morphine, meperidine, fentanyl, or sufentanil as supplements to nitrous oxide anesthesia. Meperidine, unlike the other opioids, which did not change heart rate, consistently increased it. Hemodynamic responses to laryngoscopy and intubation were suppressed by fentanyl and sufentanil, but not by morphine or meperidine. The sufentanil group was the only group in which median norepinephrine levels remained consistently below preinduction values. The frequency with which opioids had to be administered (doses/hr) was significantly less with sufentanil than with morphine and meperidine. Meperidine produced less constriction of the pupils than the other opioids and the duration of miosis was shorter. Fentanyl and sufentanil were associated with a more rapid return of mental function than morphine and meperidine. Meperidine caused deleterious effects on objective tests of psychomotor and cognitive skills that were not reflected by subjective evaluation of rate of recovery from anesthesia. The authors conclude that moderate doses of fentanyl and sufentanil are better supplements to nitrous oxide anesthesia than morphine or meperidine and that fentanyl and sufentanil are equally satisfactory. Subjective effects of the opioids correlated well with changes in pupil diameter.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6230953

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  10 in total

1.  Low-dose sufentanil as a supplement to halothane/N2O anaesthesia in infants and children.

Authors:  J A Glenski; R H Friesen; G A Lane; S Young; J Glascock
Journal:  Can J Anaesth       Date:  1988-07       Impact factor: 5.063

Review 2.  Sufentanil. A review of its pharmacological properties and therapeutic use.

Authors:  J P Monk; R Beresford; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

3.  Pupil size and light reactivity in hypothermic infants and adults.

Authors:  R C Huet; G F Karliczek; N R Coad
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

4.  Low-dose sufentanil and lidocaine supplementation of general anaesthesia.

Authors:  D C Cheng; F Chung; K R Chapman; J Romanelli
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

5.  Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; W Binstock; D W Coalson; T Cutter; D C Flemming; B Glosten
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Unintentional intraoperative awareness during sufentanil anaesthesia for cardiac surgery.

Authors:  I Gilron; P Solomon; G Plourde
Journal:  Can J Anaesth       Date:  1996-03       Impact factor: 5.063

7.  Which potent opioid? Important criteria for selection.

Authors:  J G Bovill
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

8.  Analgesics and ENT surgery. A clinical comparison of the intraoperative, recovery and postoperative effects of buprenorphine, diclofenac, fentanyl, morphine, nalbuphine, pethidine and placebo given intravenously with induction of anaesthesia.

Authors:  A A van den Berg; N M Honjol; N V Prabhu; S Datta; C J Rozario; R Muraleedaran; D Savva
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

Review 9.  Current status of nitrous oxide use in pediatric patients.

Authors:  Nishkarsh Gupta; Anju Gupta; Vishnu Narayanan M R
Journal:  World J Clin Pediatr       Date:  2022-03-09

10.  Real-time video communication between ambulance paramedic and scene - a simulation-based study.

Authors:  Roman Sonkin; Eli Jaffe; Oren Wacht; Helena Morse; Yuval Bitan
Journal:  BMC Health Serv Res       Date:  2022-08-17       Impact factor: 2.908

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.